Cancer Therapeutics, Incorporated (OTCBB: CTHP) is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in the company's pipeline.
Cancer Therapeutics' business model is to partner with existing private companies and provide its partners and investments additional funding and guidance. The company recently announced its first acquisition- a 25% ownership in NanoTherapies, LLC. NanoTherapies products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells.
NanoTherapies, LLC is run by Dr Mark Kester, a Distinguished Professor of Pharmacology, and the former Pharmacology Department Head at Penn State University College of Medicine. A leader in NanoMedicine at Penn State, he is a serial health care entrepreneur with notable technology commercialization successes in the fields of improved stents, nanoliposome’s, and the therapeutic applications of Ceramide for cancer treatment.
NanoTherapies was formed in an equity partnership with Keystone Nano (KN) to commercialize and fund further development of intellectual properties and patents developed by Keystone Nano creating distinctive cancer therapies by embedding pharmaceuticals inside smart calcium phosphate particles developed at Penn State University.
While many companies are working on dramatic new treatments, there are opportunities to make significant improvement to the present ones. This is NanoTherapies’s present objective. NanoTherapies plans to capitalize on this opportunity by employing an efficient strategy for commercialization, NDAs under 505(b) (2), and using external resources with the requisite skills and expertise, coordinated outsourcing. Used together these will minimize capital requirements and shorten the time to revenue and earnings thus crating significant value for investors. The Company’s lead product is a NanoJacketed Version of an existing and approved medication. The company intends to create a patent protected version of this medication that achieves sales of greater than $500 million a year. 
The company has the support of Keystone Nano, the Ben Franklin Partnership, Penn State, Hershey Medical, and a major corporate partner, Nalco. Given the status of competitors in this field NanoTherapies has the opportunity to commercialize an important Cancer Therapeutic through the application of a novel nanotechnology.
NanoJackets(TM) are able to increase the efficacy of existing cancer therapeutics including:
Nanotechnology refers to the interactions of cellular and molecular components and engineered materials—typically, clusters of atoms, molecules, and molecular fragments into incredibly small particles—between 1 and 100 nm. Nanometer-sized particles have novel optical, electronic, and structural properties that are not available either in individual molecules or bulk solids. The concept of nanoscale devices has led to the development of biodegradable self-assembled nanoparticles, which are being engineered for the targeted delivery of anticancer drugs and imaging contrast agents. Nanoconstructs such as these should serve as customizable, targeted drug delivery vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. Such “smart” multifunctional nanodevices hold out the possibility of radically changing the practice of oncology, allowing easy detection and then followed by effective targeted therapeutics at the earliest stages of the disease. 
In 2009, about 562,340 Americans are expected to die of cancer, more than 1,500 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. In the US, cancer accounts for nearly 1 of every 4 deaths. The number of people with a personal history of cancer living in the US has continued to rise, and is expected to double by the year 2030 to more than 20 million. The National Cancer Institute (NCI) estimates that there are presently more than 11 million cancer survivors in the US, more than 3 times the number in 1970.
The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. The National Institutes of Health (NIH) estimates overall costs of cancer in 2008 at $228.1 billion: